We fund and conduct clinical trials that accelerate breakthroughs in gastro-intestinal (GI) cancer treatment, improving outcomes for patients and their families. Gastro-Intestinal (GI) cancer is the most common form of cancer in Australia. It affects more than 37,780 Australians each year and claims 50 lives every day. GI cancer includes cancers of the digestive system – oesophagus, stomach, liver
, gallbladder and biliary tract, pancreas, large and small bowel, re**um and a**s. Despite its prevalence, survival rates remain low: the chance of surviving five years after diagnosis is just 48.4%. By uniting a diverse network of brilliant clinicians, researchers, and community advocates, we deliver clinical trials that lead to better treatments, improved quality of life, and longer survival. Since 1991, we’ve conducted 90 research studies, giving more than 9,930 people access to promising new treatments, faster. They test whether new treatments work better than the current standard of care, and they’re essential to ensuring new therapies are safe, effective, and ready to be used more widely. For patients, clinical trials can offer immediate access to the latest treatments and often improve both outcomes and quality of life. Running trials here in Australia means people can benefit from these advances up to five years earlier than if the trials were held overseas.
